Daniel Hopkins is a physician.
Gilead's $1,000-a-pill antiviral remdesivir is no wonder drug. We knew this when it failed for hepatitis, the disease it was created for. And then when it failed for Ebola. And then again, when it failed for COVID-19.
But like a bolt, in late April, a breakthrough: in a second trial for COVID-19 patients, remdesivir sped time to recovery—proof of benefit,
Read more...
On April 29th Anthony Fauci announced the National Institute of Allergy and Infectious Diseases, an institute he runs, had completed a study of the antiviral remdesivir for COVID-19. The drug reduced time to recovery from 15 to 11 days, he said, a breakthrough proving "a drug can block this virus." Now people are clamoring for $1,000-a-pill remdesivir.
While the results were preliminary, unpublished, and unconfirmed by ...
Read more...
In January, we learned of an emerging threat in China, a variant of the frightening SARS virus, but worse—more infectious. Since then, we learned China, the first to both see and successfully manage its outbreak, seriously under-detected the disease. According to a widely circulated computer model study, true cases were probably around seven times greater than the official count. Calculations published a ...
Read more...
Get free updates delivered free to your inbox.
Kevin Pho, MD shares the stories of the many who intersect with our health care system but are rarely heard from.
![\"Quantcast\"/](\"//pixel.quantserve.com/pixel/p-9b8RJMzccQ21I.gif\")
Past 6 Months
Delivering health care at a retail clinic isn’t something to be proud of
Niran S. Al-Agba, MD | PhysicianA physician’s experience of bigotry in medicine
K. C. Ardem, MD | PhysicianI’m a doctor in a family of COVID deniers
Nicholas Stark, MD, MBA | PhysicianHow MOC is contributing to the demise of physicians
Torie S. Sepah, MD | PhysicianDoctors are fleeing the medical field. Here’s why.
Anna Gladstone, DO | PhysicianThe cancel culture and the erasure of less just times and imperfect people
Andrew Pickens, MD, JD, MBA | Policy